Topic: Elan Corporation plc
Irish drugmaker Elan Corp. reported a third-quarter net loss of $43.6 million ((EURO)31.6 million) Wednesday as it paid down debts, cut research and development costs, and focused on increasing sales of drugs that combat multiple sclerosis.. Elan's share of revenue from its ...
Elan (ELN) is contemplating a spin-off of its drug delivery business, Elan Drug Technologies, in a bid to separate it from the company's successful biopharmaceutical business, it says. The notional split, announced April 19, would create two publicly traded companies, BioNeurology and ...
Elan (ELN) is contemplating a spin-off of its drug delivery business, Elan Drug Technologies, in a bid to separate it from the company's successful biopharmaceutical business, it says. The notional split, announced April 19, would create two publicly traded companies, BioNeurology and ...
Large Body of Data on Tysabri to Be Presented at Annual Meeting of the American Academy of Neurology
Data suggests improvement across broad range of functional and quality of life measures -. The presented data, based on post-hoc analyses and patient-reported outcomes studies, highlights the ability of TYSABRI (natalizumab), in some multiple sclerosis (MS) patients, to improve sustained visual function, ...
Elan Corp. PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow.. Elan said it expects to record a healthy ...
Federal health officials warned doctors Friday that the risk of a deadly brain inflammation linked to the multiple sclerosis treatment Tysabri increases with use of the drug. Tysabri has been plagued for years by rare cases of progressive multifocal leukoencephalopathy, or PML, ...
ELN) today announced data presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) showing the potential of TYSABRI? (natalizumab) to redefine successful multiple sclerosis (MS) therapy. ? Promoted regeneration or stabilization of damage to ...
ELN) today announced data presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) showing the potential of TYSABRI ? (natalizumab) to redefine successful multiple sclerosis (MS) therapy. Significantly improves measures of physical and cognitive ...
Elan Corp. Plc. and Biogen Idec Inc. said the PLEX study has shown that plasma exchange accelerates the removal of TYSABRI (natalizumab) from blood serum in patients and may help improve central nervous system immune response based on an in vitro model.. ...
Additional data suggests improvement in TYSABRI patients across clinical and patient-reported outcomes --. "TYSABRI is changing the way neurologists and patients define success in the treatment of MS," said Michael Panzara, M.D., M.P.H., vice president and chief medical officer of neurology, Biogen ...
